PCN73 Economic Analysis of the Use of Crizotinib, a Tyrosine Kinase ALK Inhibitor, in the Treatment of ALK Positive Non-Small Cell Lung Cancer in the Mexican Setting
Abstract
Authors
J.G. Gay-Molina R. Sánchez-Kobashi E. Muciño-Ortega C.I. Gutiérrez-Colín R.M. Galindo-Suárez